Nemaura Medical (NMRD) – StreetInsider.com Reports
-
Nemaura Medical (NMRD) Receives Positive Nasdaq Listing Decision
-
Nemaura Medical (NMRD) Enters $10M Non-Dilutive Credit Facility to Fuel Strategic Growth
-
Nemaura Medical (NMRD) Provides Update on Nasdaq Compliance Status and Process
-
Nemaura Medical (NMRD) Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program
-
Nemaura Medical Inc (NMRD) PT Lowered to $8.50 at Ascendiant Capital
-
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.08%
-
Nemaura Medical Inc (NMRD) PT Lowered to $2.50 at H.C. Wainwright
-
Nemaura Medical (NMRD) Announces SFDA Approval of sugarBEAT
-
Nemaura Medical (NMRD) Announces 4.8M Share Offering by Selling Stockholders
-
Nemaura Medical (NMRD) Announces Receipt of Notice from Nasdaq
-
Nemaura Medical Inc (NMRD) PT Lowered to $7 at H.C. Wainwright
-
Nemaura Medical Inc (NMRD) PT Lowered to $6 at EF Hutton
-
Nemaura Medical (NMRD) Prices 4.8M Share Offering at $1.75/sh
-
Nemaura Medical (NMRD) Receives First Purchase Order from U.S. Health Provider HealthFleet
-
Nemaura Medical Inc (NMRD) PT Lowered to $13 at Ascendiant Capital
-
Nemaura Medical (NMRD) and EVERSANA sign preliminary agreement for large-scale launch of Nemaura’s Diabetes Management Program in the U.S.
-
Nemaura Medical Inc (NMRD) PT Lowered to $8 at H.C. Wainwright
-
Nemaura Medical Inc. (NMRD) Misses Q2 EPS by 3c
-
Nemaura Medical (NMRD) Announces $5M Non-Dilutive Funding
-
UPDATE: H.C. Wainwright Starts Nemaura Medical Inc (NMRD) at Buy
-
Nemaura Medical (NMRD) Files 224.6M Mixed Shelf
-
Nemaura Medical (NMRD) Appoints Arash Ghadar as COO
-
Nemaura Medical (NMRD) halted on volatility after gaining 15% off the open
-
Nemaura Medical (NMRD) Announces Commercial Agreement with UK Licensee
-
Nemaura Medical (NMRD) Appoints Osama Hamdy to its Advisory Board
-
Nemaura Medical Inc (NMRD) PT Raised to $18 at Ascendiant Capital
-
Nemaura Medical Inc (NMRD) PT Raised to $17 at Ascendiant Capital
-
Nemaura Medical (NMRD) Trades at High, Up 140%
-
Nemaura Medical (NMRD) Announces Submission to German Authorities for Reimbursement of its Glucose Monitoring Device
-
Ascendiant Capital Assumes Nemaura Medical Inc (NMRD) at Buy, Following Earnings
-
Nemaura Medical (NMRD) Announces Correction and Pricing of Public Offering of Common Stock, Warrants
-
Nemaura Medical (NMRD) Announces Proposed Common Share Offering
-
Nemaura Medical (NMRD) Reports Results and Provides Business Update
-
Nemaura Medical (NMRD) Provides 2019 Year-End Corporate Update
-
Nemaura Medical (NMRD) Announces CE Mark Approval of SugarBEAT
-
Nemaura Medical (NMRD) Prices Up to $2.5M Common Share Offering at $1.04/Sh
-
Nemaura Medical (NMRD) Announces Proposed Common Offering
-
Nemaura Medical (NMRD) Reports Completion of Clinical Studies to Support SugarBEAT FDA De-Novo 510(k) Submission
-
Nemaura Medical (NMRD) Announces Positive Interim Data from Clinic Portion of SugarBEAT FDA Clinical Trial
-
Nemaura Medical (NMRD) Reports Positive Interim Data from Home-Use Portion of SugarBEAT Study
-
Nemaura Medical (NMRD) SugarBEAT Study Show Positive Results in European Clinical Program
-
Nemaura Medical (NMRD) halted LUDP
Back to NMRD Stock Lookup